IP Library Granted Patent US 12,593,863
Granted Patent B2
US 12,593,863 · App. 18/248,077 · Granted Apr 7, 2026

Probiotics to prevent cognitive dysfunction

Inventors: Sile Griffin (Kantvik, FI); Elaine Patterson (Kantvik, FI); Markus Lehtinen (Kantvik, FI)
Assignee: INTERNATIONAL N&H DENMARK APS
A23L33/135A61K35/744A61P25/28A61K2035/115
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,593,863
App. No.
18/248,077
Granted
Apr 7, 2026
Kind
B2
Abstract

This invention relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments in a subject in need thereof. This invention also relates to bacteria of the species Lacticaseibacillus paracasei for use in preventing or treating cognitive impairments induced by sleep deprivation and/or insufficient sleep in a subject in need thereof.

Claims (7)

1 . A method for treating cognitive impairments induced by sleep deprivation or insufficient sleep or both in a subject in need thereof, wherein the sleep deprivation or the insufficient sleep or both are due to a sleep disorder, comprising:

administering to the subject an effective amount of a combination of DGCC4981 (Lpc-37), registered at the DSMZ under deposit number DSM3261 on Oct. 5, 2017 of the species Lacticaseibacillus paracasei, Lactiplantibacilllus plantarum strain Lp-115,

and Bifidobacterium animalis ssp. lactis DGCC420 (B420) registered at the DSMZ under deposit number DSM32073 on Jun. 30, 2015.

2 . The method according to claim 1 , wherein the sleep disorder is selected from one or more of sleep apnea, narcolepsy, insomnia and parasomnia.

3 . The method according to claim 1 , wherein the combination is administered to the subject as part of a food product, a food ingredient, a dietary supplement or a pharmaceutical composition.

4 . The method according to claim 1 , wherein the effective amount is 1.5×10 9 Colony-Forming Units of the combination per dose.

5 . The method according to claim 1 , wherein the effective amount ranges from 10 6 Colony-Forming Units to 10 12 Colony-Forming Units of the combination per dose.

Assignments (1)
CHANGE OF NAME Recorded Feb 6, 2024
From: DUPONT NUTRITION BIOSCIENCES APS
To: INTERNATIONAL N&H DENMARK APS
Reel/Frame 066494/0814 →
Priority Claims (1)
EP 20201075 · Oct 9, 2020 · regional
Continuity (1)
Related Publication 20230380471A1 · Nov 30, 2023
References Cited (8)
US 20230277608A1 · Stenman · 2023 [cited by examiner]
US 20250032560A1 · Stenman · 2025 [cited by examiner]
WO WO2019121669A1 · 2019 [cited by examiner]
Albee, Journal of Primary Prevention, 2004; 24(4): 419-436 (Year: 2004). [cited by examiner]
Mayo Clinic, MCI-diagnosis and treatment; https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/diagnosis-treatment/drc-20354583?p=1; Oct. 2024 (Year: 2024). [cited by examiner]
Mayo Clinic, MCI-summary and prevention; https://www.mayoclinic.org/diseases-conditions/mild-cognitive-impairment/symptoms-causes/syc-20354578; Oct. 2024 (Year: 2024). [cited by examiner]
Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/4865-learning-disabilities-what-you-need-to-know; Jan. 2024 (Year: 2024). [cited by examiner]
Cleveland Clinic, https://my.clevelandclinic.org/health/diseases/24976-neurodegenerative-diseases#prevention; May 2023 (Year: 2023). [cited by examiner]